• 대한한방내과학회지
• /
• 제39권4호
• /
• pp.802-813
• /
• 2018

This case report describes a patient with olivopontocerebellar atrophy accompanied by sleep disorder and gait disturbance whose condition was improved by treatment with Korean medicine. The 61-year-old woman, who was diagnosed with olivopontocerebellar atrophy (Multiple Systemic Atrophy-Cerebellum), was admitted to hospital twice and treated with Korean medicine (acupuncture and herbal medicine) and rehabilitation. The Korean medicine was Gwibiondam-tang-gami and Jaeumgeonbi-tang-gami. Clinical symptoms were assessed by the Modified Bathel index, functional independent measurement, Berg balance scale, and Unified Multiple System Atrophy rating scale. A brain MRI at the one-year follow up after onset showed similar progress but clinical symptoms were improved after treatment, and the evaluation index score increased. Multiple system atrophy, a type of degenerative neurological disease, has no targeted treatment. In this situation, although this report describes a single case, Korean medicine treatment could provide a meaningful improvement in the sleep disturbance and gait disorder symptoms of patients with olivopontocerebellar atrophy.

• 대한한의학회지
• /
• 제32권2호
• /
• pp.118-125
• /
• 2011

난치성 질환인 다발성 뇌신경계 위축증으로 진단 받은 환자를 신음허, 비기허, 중풍으로 변증하고 한약 치료, 침구 치료 및 재활 치료를 시행한 결과 근력 및 연하기능이 호전된 경과를 관찰하였기에 보고하는 바이다. 향후 다발성 뇌신경계 위축증에 대한 한방치료 효과를 증명하기 위해 추가적인 증례 보고와 다양한 실험 및 임상연구가 필요할 것으로 사료된다.

• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 2005년도 제44차 추계학술대회 및 총회
• /
• pp.347.1-347.1
• /
• 2005

• 대한한의학회지
• /
• 제21권4호
• /
• pp.286-291
• /
• 2000

Behcet's disease is a systemic disease affecting multiple organs including the central nervous system. Neuro-Behcet's disease was regarded as relatively rare, but thanks to the development of diagnostic tools, more and more cases are being reported. We are reporting a case of neuro-Behcet's disease in which the patient displayed paraparesis, dysarthria and involuntary tremor as neurologic symptoms. The patient's brain MRI showed cerebellar atrophy, and a spinal cord MRI failed to reveal any significant lesions. The patient experienced a couple of fever attacks during hospitalization, which were managed adequately by herbal medicines. Her main neurological symptoms such as paraparesis were, however, grossly unchanged at discharge.

• Journal of Yeungnam Medical Science
• /
• 제38권1호
• /
• pp.27-33
• /
• 2021

The gut is a complex organ that has played an important role in digestion, absorption, endocrine functions, and immunity. The gut mucosal barriers consist of the immunologic barrier and nonimmunologic barrier. During critical illnesses, the gut is susceptible to injury due to the induction of intestinal hyperpermeability. Gut hyperpermeability and barrier dysfunction may lead to systemic inflammatory response syndrome. Additionally, gut microbiota are altered during critical illnesses. The etiology of such microbiome alterations in critical illnesses is multifactorial. The interaction or systemic host defense modulation between distant organs and the gut microbiome is increasingly studied in disease research. No treatment modality exists to significantly enhance the gut epithelial integrity, permeability, or mucus layer in critically ill patients. However, multiple helpful approaches including clinical and preclinical strategies exist. Enteral nutrition is associated with an increased mucosal barrier in animal and human studies. The trophic effects of enteral nutrition might help to maintain the intestinal physiology, prevent atrophy of gut villi, reduce intestinal permeability, and protect against ischemia-reperfusion injury. The microbiome approach such as the use of probiotics, fecal microbial transplantation, and selective decontamination of the digestive tract has been suggested. However, its evidence does not have a high quality. To promote rapid hypertrophy of the small bowel, various factors have been reported, including the epidermal growth factor, membrane permeant inhibitor of myosin light chain kinase, mucus surrogate, pharmacologic vagus nerve agonist, immune-enhancing diet, and glucagon-like peptide-2 as preclinical strategies. However, the evidence remains unclear.

• Journal of Oral Medicine and Pain
• /
• 제25권2호
• /
• pp.159-165
• /
• 2000

Subsequent to an allogenic stem cell transplantation(ASCT) on patients with hematologic malignancy(AML, ALL, CML, multiple myeloma, lymphoma etc.), chronic GVHD(graft versus host disease), which is an immunological reaction, occurs. With treatment results from patients who were diagnosed with ALL(acute lymphocytic leukemia), undergone BMT(bone marrow transplantation) and showed oral and skin lesions due to GVHD, treatment of oral manifestations of leukemia and its general management were studied. 90% of patients with chronic GVHD show change in the oral mucosa causing oral manifestations such as leukoplakia, lichenoid change of the oral mucosa, mucosal atrophy, erythema, ulceration and xerostomia. In treating GVHD, extensive systemic immunosuppression cause bacterial, viral, fungal infection that are fatal, and even if the treatment is successful, the patient is already in a severe immunosuppressed state. Therefore, localized target therapy is preferred. In another words, topical application(rinse, cream, ointment etc.) of cyclosporin and steroid in treating oral chronic GVHD is highly recommended, and the use of PUVA(Psoralen Ultraviolet A) and thalidomide is reported to be effective. In treating such diseases, dental treatment to control pain and prevent secondary infection of oral manifestations is very important. To those patients with systemic diseases who show limited effect by general dental treatment, non-invasive treatment such as the dental laser, in addition to the use of drugs, may be necessary to actively treat pain and help the healing process. For greater results, new effective methods are to be developed for treatment.

• Nuclear Medicine and Molecular Imaging
• /
• 제43권1호
• /
• pp.10-18
• /
• 2009

목적: 본 연구는 다중계위축증(MSA)과 원발성 파킨슨병(IPD)의 감별 진단을 위하여 $^{123}I$-FP-CIT SPECT를 사용하여 선조체내 도파민신경시스템 및 선조체외의 모노아민시스템을 평가하였다. 대상 및 방법: 총 13명의 IPD 환자(남:여=9:4, $65.5{\pm}5.3$세), 8명의 MSA 환자(남:여=6:2, $64.0{\pm}4.5$세), 정상인 12명(남:여=8:4, $63.3{\pm}5.7$세)에게 $^{123}I$-FP-CIT SPECT를 시행하였다. 도파민 운반체 분석을 위해 선조체내 미상핵과 전, 후피각에 관심영역을 설정하고 세로토닌 운반체 분석을 위해 시상하부와 뇌교에 관심영역을 각각 정한 뒤 각 부위에서 $^{123}I$-FP-CIT의 결합잠재능(binding potential, BP=V3")을 계산하였다. V3"는 비특이적 결합에 대한 특이 결합의 비율을 이용하여 구하였고 비특이적 결합 부위는 후두엽 영역에서 계수를 측정하였다. 결과: 선조체 전체 및 미상핵과 전후피각 각각에서의 도파민 운반체의 농도는 MSA와 IPD환자 모두에서 정상인에 비해 현저한 감소를 나타내었다(p<0.05). 특히 IPD환자 군에서는 후측 피각에서의 도파민 운반체 농도에 심한 감소를 보여 전후피각비가 정상군에 비하여 유의하게 증가되었으며($1.55{\pm}0.34$ vs. $1.29{\pm}0.06$, p=0.026), 미상핵/피각비은 증가된 양상을 보였으나 유의수준에 도달하지는 못하였다($1.24{\pm}0.20$ vs. $1.11{\pm}0.06$, p=0.23). MSA의 경우 전후피각비($1.32{\pm}0.19$)와 미상핵/피각비($1.07{\pm}0.25$)에서 정상군과 차이가 없었다. 세로토닌 운반체에 의한 뇌교에서의 섭취는 MSA환자군에서 정상군 및 IPD환자군에 비하여 감소되어 있는 경향을 나타내었으며(정상:$0.33{\pm}0.19$, IPD: $0.29{\pm}0.19$, MSA: $0.22{\pm}0.1$) 시상하부에서는 각 군에서 뚜렷한 차이가 없었다. 결론: 본 연구에서 $^{123}I$-FP-CIT SPECT 영상을 이용하여 IPD와 MSA환자의 선조체 도파민 운반체의 감소정도와 양상을 평가하고, 뇌교 및 시상하부에서의 세로토닌 운반체 섭취의 감소를 평가하였다. $^{123}I$-FP-CIT SPECT에 의한 선조체내 도파민 운반체 변화 및 뇌교에서의 세로토닌 운반체의 변화의 가시화 및 정량화는 MSA와 IPD의 조기 감별에 도움이 유용할 것이다.